Offers

Quote

anonymous

Guest
Contingent offers are a big risk. Good candidates will get multiple job offers and have to decide whether they want to wait for Aimmune’s FDA Advisory Board Meeting. I think this strategy will backfire. They should consider bringing highly desired talent or talent in key markets on early (LA, SF, NY, TX, CHI, FL, ATL, etc). There’s no reason top markets shouldn’t have PAM’s working in the field doing premarket work.

The ICER report is negative and demonstrates a lack of understanding of the purpose of OIT. Most ICER reports are negative, but allergists and payers understand the importance of this therapy. OIT is VERY important for a lot of patients, particularly pediatric patients. 2-3 million people have peanut allergies and a drug that can offer some desensitization and minimize life threatening risks is a win for the patient. This is a great opportunity, however the conservative approach means they might lose some good field talent.

Good luck to all of you who are interviewing and looking forward to August panel interviews.
 






anonymous said:
Contingent offers are a big risk. Good candidates will get multiple job offers and have to decide whether they want to wait for Aimmune’s FDA Advisory Board Meeting. I think this strategy will backfire. They should consider bringing highly desired talent or talent in key markets on early (LA, SF, NY, TX, CHI, FL, ATL, etc). There’s no reason top markets shouldn’t have PAM’s working in the field doing premarket work.

The ICER report is negative and demonstrates a lack of understanding of the purpose of OIT. Most ICER reports are negative, but allergists and payers understand the importance of this therapy. OIT is VERY important for a lot of patients, particularly pediatric patients. 2-3 million people have peanut allergies and a drug that can offer some desensitization and minimize life threatening risks is a win for the patient. This is a great opportunity, however the conservative approach means they might lose some good field talent.

Good luck to all of you who are interviewing and looking forward to August panel interviews.
Click to expand...

Conservative approach? The company was originally only bringing 40 on in Sept, now they are bringing all 80. The drug isn't getting approved till January at best. They are doing prework.
 






anonymous said:
Contingent offers are a big risk. Good candidates will get multiple job offers and have to decide whether they want to wait for Aimmune’s FDA Advisory Board Meeting. I think this strategy will backfire. They should consider bringing highly desired talent or talent in key markets on early (LA, SF, NY, TX, CHI, FL, ATL, etc). There’s no reason top markets shouldn’t have PAM’s working in the field doing premarket work.

The ICER report is negative and demonstrates a lack of understanding of the purpose of OIT. Most ICER reports are negative, but allergists and payers understand the importance of this therapy. OIT is VERY important for a lot of patients, particularly pediatric patients. 2-3 million people have peanut allergies and a drug that can offer some desensitization and minimize life threatening risks is a win for the patient. This is a great opportunity, however the conservative approach means they might lose some good field talent.

Good luck to all of you who are interviewing and looking forward to August panel interviews.
Click to expand...
 












anonymous said:
Contingent offers are a big risk. Good candidates will get multiple job offers and have to decide whether they want to wait for Aimmune’s FDA Advisory Board Meeting. I think this strategy will backfire. They should consider bringing highly desired talent or talent in key markets on early (LA, SF, NY, TX, CHI, FL, ATL, etc). There’s no reason top markets shouldn’t have PAM’s working in the field doing premarket work.

The ICER report is negative and demonstrates a lack of understanding of the purpose of OIT. Most ICER reports are negative, but allergists and payers understand the importance of this therapy. OIT is VERY important for a lot of patients, particularly pediatric patients. 2-3 million people have peanut allergies and a drug that can offer some desensitization and minimize life threatening risks is a win for the patient. This is a great opportunity, however the conservative approach means they might lose some good field talent.

Good luck to all of you who are interviewing and looking forward to August panel interviews.
Click to expand...
Many have received offers and openings are being filled fast.
 








































































Haha $79 pps. you sure you didn't mean $7.90 pps? No way this takes off. The treatment is just not efficacious enough to warrant the every 2 week visit, in which it will be uncomfortable for the patient. Its like going to the dentist every 2 weeks. You think people would like going to the dentist every 2 weeks for 6 months? haha
 






anonymous said:
Yes, some doctors are doing OIT by trial and error with varying degrees success- w/o insurance coverage.

You see how this is different, don’t you? Smarten up buttercup!
Click to expand...
Buttercup is smart. Allergist in territory I interviewed for has desensitized 800 patients to date. Takes the ‘trial and error’ off the table. Might want to check this out if considering offer.
 






anonymous said:
Buttercup is smart. Allergist in territory I interviewed for has desensitized 800 patients to date. Takes the ‘trial and error’ off the table. Might want to check this out if considering offer.
Click to expand...

Sorry you didn’t get an offer.

I checked with a pediatric allergist at a major academic medical center. This is going to be BIG! I can’t wait...
 












Top Bottom
Back
Quote